		7/604
Substitute for form 1449A-B/PTO	Co	emplete if Known
	Application Number	10/084,706 10/609,296 "Catio
INFORMATION DISCLOSURE	Filing Date	February 26, 2002 June 27, 2003
STATEMENT BY APPLICANT	First Named Inventor	Rasmussen, et al.
	Group Art Unit	1647
	Examiner Name	J. Seharaseyon
(use as many sheets as necessary)	Attorney Docket Number	0228us410 0228us420

	U.S. PATENT DOCUMENTS								
		U.S. Patent Docun	nent	Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, lines,			
Examiner Initials	Cite No.	Number	Kind Code (if known)	Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appeal			

					N PATENT DOCUMEN			
Examiner Initials	Cite No.	Office	Foreign Patent Docur	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
/JS/	1	EP	0 287 075	B2	Dr. Rentschler Biotechnologie GmbH	10/19/1988		X
/JS/	2	EP	0 287 075 (English language translation of document AY)	B2	Dr. Rentschler Biotechnologie GmbH	10/19/1988		
/JS/	3	wo	01/15736	A2	Maxygen ApS	03/08/2001		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
/JS/	4	O'CONNELL, et al., "The Influence of Flanking Sequences on O-Glycosylation", Biochemical and Biophysical Research Communications, 1991, pp. 1024-1030, 180:2.	
		300000000000000000000000000000000000000	
		8000090000000	

Considered Vol10/2007	Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	08/15/2007
-------------------------	-----------------------	---------------------------	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Co	omplete if Known
	Application Number	09/648,569 10/609,296
INFORMATION DISCLOSURE.	Filing Date	August 25, 2000 June 27, 2003
STATEMENT BY APPLICANT	First Named Inventor	A. H. Pedersen Poul B. Rasmussen
	Group Art Unit	1647
	Examiner Name	J. Seharaseyon
(use as many sheets as necessary)	Attorney Docket Number	0202us810 0228us420

		U.S. Patent Do	cument	Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, lines,
Examiner Initials	Cite No.	Number	Kind Code (if known)	Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appeal
/JS	1	5,206,344		Katre et al.	04/27/1993	
/JS/	2	5,738,846		Greenwald et al.	04/14/1998	

				FOREIGI	N PATENT DOCUMEN	TS		
Examiner Initials	Cite No.	Office	Foreign Patent Docur	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
/JS/	3	EP	0 370 205	A2	Kyowa Hakko Kogyo Co., Ltd.	05/30/1990		
000000000000000000000000000000000000000	4	EP	0 529 300	B1	Rentschler Biotechnologie GmbH & Co.	03/03/93		X
2018/00/00/00/00/00/00/00/00/00/00/00/00/00	5	EP	0 529 300 (English language translation of document #4)	B1	Rentschler Biotechnologie GmbH & Co.	03/03/93		
	6	wo	95/27502	A1	Research Develop- ment Foundation	10/19/1995		
200000000	7	wo	98/35026	A1	Novo Nordisk A/S	08/13/1998		
V	8	wo	99/55377	A2	Applied Research Systems	11/04/1999		

	OTHER ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т				
/JS/	9	Derwent Abstract 012152872 for WO 98/48018, a German publication cited in previous IDS Form-1449.					
/JS/	10	Derwent Abstract 009442954 for EP 539 300, a French publication cited in previous IDS Form-1449.					
		000000000000000000000000000000000000000					

Examiner Signature /Jegatheesan Seharaseyon/	Date Considered	08/15/2007
--	--------------------	------------


^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

GOPY FROM PARENT

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0651-0031

	omplete if Known]
Application Number	09/648,569 10/609 296	
Filing Date	August 25, 2000 June 27, 2003	
First Named Inventor	Anders, Hielholt Pedersen Poul Rash	usseh
Group Art Unit	1633- /647	
Examiner Name	Unassigned J. Scharaseyon	
Attorney Docket Number	31-107600US 0228 U5420	

	<u> </u>		U.	S. PATENT DOCUMENTS	3	
Examiner Initials	NIK NIK		Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
/JS/	AA	4,588,585		Mark et al.	05-13-1986	
	AB	4,686,191		Itoh et al.	08-11-1987	
2000000000	AC	4,769,233		Bell et al.	09-06-1988	
Secondo	AD	4,904,584		Shaw	02-27-1990	
	AE	4,914,033		Bell et al.	04-03-1990	
0000000000	AF	4,917,888		Katre et al.	04-17-1990	
202230000	AG	4,966,843		McCormick et al.	10-30-1990	
0000000	АН	5,218,092		Sasaki et al.	08-06-1993	
	Al	5,376,567		McCormick et al.	12-27-1994	
000000	AJ	5,382,657		Hoffmann-La Roche Inc.	01-17-1995	
	AK	5,545,723		Goelz et al.	08-13-1996	
· V	AL	5,795,779		McCormick et al.	08-18-1998	

				FOREIGI	N PATENT DOCUMEN	TS		
i-	011-		Foreign Patent Docu	ment	J J J J J J J J J J J J J J J J J J J	Date of Publication	Pages, Columns, Lines,	
Examin er Initials	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Т
/JS/	AM	wo	95/25170		Biogen, Inc.	09-21-1995		
10000000000000000000000000000000000000	AN	WO	98/48018		Fraun-Hofer- Gesellschaft Zur Forderung Der Angewandten	10-29-1998		
000000000000000000000000000000000000000	AO	wo	99/03887		Bolder Biotechnology	01-28-1999		
	AP	wo	99/55377		Applied Research	11-04-1999		
	AQ	wo	99/67291		Immunex Corporation	12-29-1999		
W	AR	wo	00/23114		Biogen, Inc.	04-27-2000		

Constitution T				
Examiner		Date		7
Signature	/Jegatheesan Seharaseyon/	Date	08/15/2007	- 1
Signature	/oeganieesan Oenaraseyon/	I Considered	VOI I DI LUVI	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PARENT

(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0651-0031

31-107600US 0228US 420

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	Complete if Known]
Application Number	09/648,569 10/609, 296	1
Filing Date	August 25, 2000 June 27, 2003	1
First Named Inventor	Anders, Hjelholt Pedersen Poul Ray	nussen
Group Art Unit	1833 /647	
Examiner Name	Unassigned T. Celara (Puna	1

(use as many sheets as necessary)

/,	IS/	AS	wo	00/23472	Biogen, Inc.	04-27-2000	
		AT	wo	00/26354	Novo Nordisk	05-11-2000	
		ΑU	EP	083 069	Kyowa Hakko Kogyo Co., Ltd.	09-16-1987	
8897000000	·	ΑV	EP	041 313	Biogen, Inc.	09-12-1990	
Service control		AW	EP	229 108	Cetus Corporation	12-27-1990	
20000000		AX	EP	260 350	Cetus Corporation	02-12-1992	 •
***************************************		AY	EP	287 075	Arzeneimittelforschung /Drug Research	01-18-1995	
***************************************		AZ	ΕP	539 300	Philippe Thiriet	02-07-1996	
V		ВА	EP	593 868	Hoffmann-La Roche Inc.	04-15-1998	

Attorney Docket Number

			OTHER PRIOR ART - NON PATECNT LITERATURE DOCUMENTS	
е	Examin Cite Include name of the authors serial, symposium, of the serial control of the		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
/JS/ BB		BB	Fierlbeck et al., "Neutralising interferon β antibodies in melanoma patients treated with recombinant and natural interferon β" Cancer Immunol Immunother (1994) 39:263-268	
		ВС	Karpusas et al., "The Structure of Human Interferon- β: Implications for activity" <u>CMLS</u> 54 (1998) 1203-1216	
		BD	Karpusas et al. "The crystal structure of human interferon β at 2.2 A resolution" Proc. Nat. Acad. Sci. USA (1997) 94:11813-11818	-
000000000000000000000000000000000000000		BE	Mayorga et al., "Antibodies to Commercially Available Interferon-Bet Molecules in Multipule Sclerosis Patients Treated with Natural Interferon-Beta" Int. Arch. Allery Immunol 1999; 118:368-371	
000000000000000000000000000000000000000		BF	Munschauer et al., "Managing Side Effects of Interferon-Beta in Patients with Relapsing-Remitting Multipule Sclerosis" Clinical Therapeutics vol. 19, No. 5, 1997 883-893	
		BG	Redlich et al., "Antibodies that neutralize human β interferon biologic activity recognizing a linear epitope: Analysis by synthetic peptide mapping" Proc. Natl. Acad. Sci. USA vol. 88, pp. 4040-4044 May 1991	

Signature Todydinoodin oondrado John	Examiner	/Joanthopen Schargeoven/	Date	2014510007	\neg
Considered	Signature	/Jegatheesan Seharaseyon/	Considered	08/15/2007	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1

COPY FROM PARENT

(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0651-0031

31-107600US 022F

Substitute for form 1449A-B/PTO

Complete if Known

Application Number

Filing Date

Filing Date

First Named Inventor

Group Art Unit

(use as many sheets as necessary)

Complete if Known

Application Number

Filing Date

Filing Date

August 25, 2000

Anders, Hielholt Pedersen Poul Rasmuss

First Named Inventor

Group Art Unit

Examiner Name

Unassigned

Atternation Desired Number 21, 107 courts

Atternation Populat Number 21, 107 courts

Atternation Population Population

Attorney Docket Number

·/JS/	вн	Rudick et al., "Incidence and significance of neutralizing antibodies to interferon beta-1a in multipule sclerosis" Neurology May 1889, 50: 1266-1272
000000000000000000000000000000000000000	BI	Runkel et al., "Structural and Functional Differences Between Glycosylated and Non-Glycosylated Forms of Human Interferon- β (IFN- β) Pharmaceutical Research vol. 15, No 4, 1998, 641-649
	BJ	Runkel et al, 1998, Jour. Biol. Chem. Difference in Activity between α and β Type I Interferons Explored by Mutational Analysis" 273, No. 14, pp. 8003-8008
000000000000000000000000000000000000000	BK	Senda et al., "Refined Crystal Structure of Recombinant Murine Interferon- β at 2.15 A Resolution" J. Mil. Biol. (1995) 253, 187-207
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	BL	Stewart et al, DNA "Chemical Mutagenesis of Human Interferon- \(\beta \): Construction, Expression in E. coli, and Biological Activity of Sodium Bisulfite-Induced Mutations Vol 6 no 2 1987 p119-128
	вм	Tanigunchi, et al., "The nucleotide sequence of human fibroblast interferon cDNA" Gene 10 (1980) 11-15
V	BN	Yong et al., "Interferon beta in the treatment of multiple sclerosis" Neurology 1998; 51: 682-689

Examiner / /Jegatheesan Seharaseyon/ Date 08/15/2007	
Signature /Jegatheesan Seharaseyon/ Considered 08/15/2007	;

JUL 3 1 2006

Substitute for m 1449A-B/PTO
SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

C	omplete if Known
Application Number	10/609,296
Filing Date	June 27, 2003
First Named Inventor	Poul Baad Rasmussen
Group Art Unit	1647
Examiner Name	Jegatheesan Seharaseyon
Attorney Docket Number	0228us420

				. PATENT DOCUMENTS		
Examiner	Cite	U.S. Patent Docume Number	nt Kind	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, lines, Where Relevant Passages
Initials	No.	Number	Code (if known)	Cited Document	MM-DD-YYYY	or Relevant Figures Appeal
/JS/	1	6,531,122		Pedersen et al.	03-11-2003	
/JS/	2	2003/0175240A1 (USSN 10/325,720)		Pedersen et al.	09-18-2003	
ĴS/	3	2003/0170206A1	:	Rasmussen et al.	09-11-2003	
1001		(USSN 10/084,706)				
				STOCKED GENORIS GENORI		
		300000000000000000000000000000000000000	gotisses/gotistes/gotis			
		5070000000				

			Foreign Patent Docur		N PATENT DOCUMEN' I	Date of Publication	Pages, Columns, Lines,	Π
Examiner Initials	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T
				The state of the s				
			THE REAL PROPERTY AND THE PARTY AND THE PART					
		THE RESERVE OF THE PERSON NAMED IN	STATE OF THE PARTY					
		SKOROKOROK						

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
/JS/	4	Apweiler et al., "On the frequency of protein glycosylation, as deducted from analysis of the SWISS-PROT database," Biochim. Biophys. Acta 1473:4-8 (1999).	
/JS/	5	Wells et al., "Additivity of Mutational Effects in Proteins," Biochemistry 29(37):8509-8517 (1990).	
/JS/	6	Ngo et al., "Computation Complexity, Protein Structure Prediction, and the Levinthal Paradox," in The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495 (K. Merz Jr. and S. Le Grand, eds., 1994).	

Examiner		Date	00/45/0007
Signature	/Jegatheesan Seharaseyon/	Considered	[08/15/2007]

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.